Modulation of P-glycoprotein-mediated anticancer drug accumulation, cytotoxicity, and ATPase activity by flavonoid interactions

Nutrition and Cancer

Volumn 63, Issue 3, 2011, Pages 435-443

  Tran, Van H ^a   Marks, Denese ^a   Duke, Rujee K ^a   Bebawy, Mary ^a   Duke, Colin C ^a   Roufogalis, Basil D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 ,7 DIMETHOXYFLAVONE; 4',6', 7 TRIACETOXYISOFLAVONE; 4',6,7 TRIMETHOXYISOFLAVONE; 4',7 DIHYDROXYFLAVONE; 4',7 DIMETHOXYISOFLAVONE; ABC TRANSPORTER; ACACETIN; ADENOSINE TRIPHOSPHATASE; APIGENIN; BIOCHANIN A; CHRYSIN; CIRSIMARITIN; COLCHICINE; DAIDZEIN; DAUNORUBICIN; FLAVONE; FLAVONOID; GENISTEIN; GLYCOPROTEIN P; HESPERIDIN; NARINGENIN; OSAJIN; PSI BAPTIGENIN ACETATE; QUERCETIN; QUERCITRIN; RUTOSIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VITEXIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; FOOD DRUG INTERACTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL;

EID: 79957551963     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2011.535959     Document Type: Article

References (54)

1. Gottesman MM, Fojo T, and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2, 48-58, 2002. (Pubitemid 37328807)
2. Leith C, Kopecky K, Chen I, Eijdems L, Slovak M, et al.: Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group study. Blood 94, 1086-1099, 1999.
3. Goasguen JE, Dossot J-M, Fardel O, LeMee F, Le Gall E, et al.: Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 81, 2394-2398, 1993. (Pubitemid 23127076)
4. Chan HSL, Thorner PS, Haddad G, and Ling V: Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8, 689-704, 1990. (Pubitemid 20127254)
5. Chan HSL, Haddad G, Thorner PS, DeBoer G, Lin YP, et al.: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325, 1608-1614, 1991.
6. Baldini N, Scotlandi K, Barbandi-Brodano G, Manara MC, Maurici D, et al.: Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333, 1380-1385, 1995.
7. Linn SC, Giaccone G, van Diest PJ, et al.: Prognostic relevance of P-glycoprotein expression in breast cancer. Ann Oncol 6, 679-685, 1995.
8. Krishna R and Mayer LD: Modulation of p-glycoprotein (P-gp) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators. Curr Med Chem-Anti-Cancer Agents 1, 163-174, 2001.
9. Krystyna M, Andrzej BH, Olga WO, and Andrzej PA:. Compounds that modulate multidrug resistance in cancer cells. Cel Biol Mol Lett 6, 362-368, 2001.
10. Fresco P, Borges F, Diniz C, and Marques MP: New insights on the anticancer properties of dietary polyphenols. Med Res Rev 26, 747-766, 2006. (Pubitemid 44735552)
11. Kandaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, et al.: The antitumor activities of flavonoids. In Vivo 19, 895-909, 2005.
12. Kosmider B and Osiecka R: Flavonoid compounds: a review of anticancer properties and interactions with cis-diamminedichloroplatinum(II). Drug Dev Res 63, 200-211, 2004. (Pubitemid 40470659)
13. Lopez-Lazaro M: Flavonoids as anticancer agents: structure-activity relationship study. Curr Med Chem-Anti - Cancer Agents 2, 691-714, 2002.
14. Toshio A, Tomoyoshi A, and Shinichi A: Flavonoids of leguminous plants: structure, biological activity, and biosynthesis. J Plant Res 113, 475-48, 2000.
15. Rimm EG, Katan MB, Ascherio A, Stampfer MJ, and Willett WC: Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. Ann Intern Med 125, 384-389, 1996. (Pubitemid 126449708)
16. Ross JA and Kasum CM: Dietary flavonoids: bioavailability, metabolic effects, and safety. Ann Rev Nutr 22, 19-34, 2002. (Pubitemid 35221452)
17. Mandlekar S, Hong JL, and Kong ANT: Modulation of metabolic enzymes by dietary phytochemicals: a review of mechanisms underlying beneficial versus unfavorable effects. Curr Drug Metab 7, 661-675, 2006.
18. Morris ME and Zhang S: Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci 78, 2116-2130, 2006.
19. Shapiro AB and Ling V: Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250, 130-137, 1997. (Pubitemid 27504592)
20. Conseil G, Baubichon-Cortay H, Dayan G, Jault JM, Barron D, et al.: Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 95, 9831-9836, 1998.
21. Castro AF and Altenberg GA: Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. Biochem Pharmacol 53, 89-93, 1997. (Pubitemid 26419790)
22. Ferte J, Kuhnel JM, Chapius G, Rolland Y, Lewin G, et al.: Flavonoid-related modulators of multidrug resistance: synthesis, pharmacological activity, and structure-activity relationships. J Med Chem 42, 478-489, 1999.
23. Critchfield JW, Welsh CJ, Phang JM, and Yeh GC: Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells: activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol 48, 1437-1445, 1994.
24. Phang JM, Poore CM, Lopaczynska J, and Yeh GC: Flavonol - stimulated efflux of 7,12-dimethylbenz(a)anthracene inmultidrug-resistant breast cancer cells. Cancer Res 15, 5977-5981, 1993. (Pubitemid 24006169)
25. Bebawy M, Morris MB, and Roufogalis BD: Selective modulation of P-glycoprotein-mediated drug resistance. Br J Cancer 85, 1998-2003, 2001.
26. Syed SK, Christopherson RI, and Roufogalis BD: Reversal of vinblastine transport by chlorpromazine inmembrane vesicles from multidrug-resistant human CCRF-CEM leukaemia cells. Br J Cancer 78, 321-327, 1998. (Pubitemid 28336417)
27. 100 cells by Gynostemma pentaphyllum extract. Phytomed 14, 830-839, 2007.
28. Bebawy M and Chetty M: Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia. Bioessays 30, 183-188, 2008. (Pubitemid 351196953)
29. Kyle JAM and Duthie GG: Flavonoids in foods. In: Flavonoids, Chemistry, Biochemistry, and Applications, Anderson OM and Markham KR (eds.). Boca Raton, FL: CRC Press, Taylor & Francis Group, 2006, pp. 219-262.
30. Jaganathan SK and Mandal M: Antiproliforative effects of honey and of its polyphenol: a review. J Biomed Biotechnol 2009; Article ID 830616.
31. Falcao SI, Vilas-Boas M, Estevinho LM, Barros C, Domingues MR, et al.: Phenolic characterization of Northeast Portuguese propolis: usual and unusual compounds. Anal Bioanal Chem 396, 887-897, 2010.
32. Bruneton J: Pharmacognosy, Phytochemistry, Medicinal Plants, 2nd ed. Lavoisier Publishing, Paris, France, 1999.
33. Whaley WL, Rummel JD, Zemenu E, Li W, Yang P, et al.: Isolation and characterization of osajin and pomiferin: discovery laboratory exercises for organic chemistry. Chemical Educator 12, 179-184, 2007.
34. Markham KR and Mabry TJ: The identification of twenty-three 5-deoxy and 10-5-hydroxy flavanoid from Baptisia lecontei (Leguminaceae). Phytochem 7, 791-801, 1968.
35. Khan IA, Avery MA, Burrant CL, Goins DK, Mikell JR, et al.: Antigiardial activity of isoflavones from Dalbergia frutescens bark. J Nat Prod 63, 1414-1416, 2000.
36. Marks DC, Davey MW, Davey RA, and Kidman AD: Differentiation and multidrug resistance in response to drug treatment in the K562 human leukaemia cell line. Br J Haematol 84, 83-89, 1993. (Pubitemid 23158119)
37. Zamora JM, Pearce HL, and Beck WT: Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33, 454-62, 1988.
38. Schwab D, Fischer H, Tabatabaei A, Poli S, and Huwyler J: Comparison of in vitro p-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem 46, 1716-1725, 2003. (Pubitemid 36444224)
39. Litman T, Zeuthen T, Skovsgaard T, and Stein WD: Competitive, non-competitive, and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta - Molecular Basis of Disease 1361, 169-176, 1997. (Pubitemid 27362090)
40. Richardson MA, Sanders T, Palmer JL, Greisinger A, and Singletary SA: Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18, 2505-2514, 2000. (Pubitemid 30432515)
41. Davey M, Hargrave R, and Davey R: Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukeamia cells. Leukemia Res 20, 657-664, 1996. (Pubitemid 26364746)
42. Zhang S and Morris ME: Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304, 1258-1267, 2003. (Pubitemid 36254439)
43. Jodoin J, Demeule M, and Beliveau R: Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 1542, 149-159, 2002.
44. Di Pietro A, Conseil G, Perez-Victoria JM, Dayan G, Baubichon-Cortay H, et al.: Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci 59, 307-322, 2002. (Pubitemid 34169516)
45. Hashimoto T, Kumazawa S, Nanjo F, Hara Y, and Nakayama T: Interaction of tea catechins with lipid bilayers investigated with liposome systems. Biosci Biotechnol Biochem 63, 2252-2255, 1999. (Pubitemid 129549060)
46. Loke WM, Hodgson JM, Proudfoot JM, McKinley AJ, Puddey IB, et al.: Pure dietary flavonoids quercetin and (-)-epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men. Am J Clin Nutr 88, 1018-1025, 2008.
47. Aldercreutz H and Mazur W: Phyto-oestrogens and Western diseases. Ann Med 29, 95-120, 1997.
48. Graefe EU, Witting J, Mueller S, Riethling AK, Uehleke B, et al.: Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 41, 492-499, 2001. (Pubitemid 32381866)
49. Heo MY, Sohn SJ, and Au WW: Antigenotoxicity of galangin as a cancer chemopreventive agent candidate. Mut Res 488, 135-150, 2001. (Pubitemid 32436428)
50. Schramm DD, Wang JF, Holt RR, Ensunsa JL, Gonsalves JL, et al.: Chocolate procyanidins decrease the leukotriene-prostacyclin ratio in humans and human aortic endothelial cells. Am J Clin Nutr 73, 36-40, 2001. (Pubitemid 32016813)
51. Tixier JM, Godeau G, Robert AM, and Hornebeck W: Evidence by in vivo and in vitro studies that binding of pycnogenols to elastin affects its rate of degradation by elastases. Biochem Pharmacol 33, 3933-3939, 1984. (Pubitemid 15135022)
52. Perez-Victoria JM, Chiquero MJ, Conseil G, Dayan G, Di Pietro A, et al.: Correlation between the affinity of flavonoids binding to cytosolic site of Leishmania tropica multidrug trans-porter and their efficiency to revert parasite resistance to daunomycin. Biochem 38, 1736-1743, 1999.
53. Mitsunaga H, Takanaga H, Matsuo M, Naito T, Tsuruo, et al.: Effect of bioflavonoids on vincristine transport across blood-brain barrier. Eur J Pharmacol 395, 193-201, 2000. (Pubitemid 30254368)
54. Sadzuka Y, Sugiyama T, and Sonobe T: Efficacies of tea components on doxorubicin induced antitumor activity and reversal ofmultidrug resistance. Toxicol Lett 114, 155-162, 2000. (Pubitemid 30125452)